Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2003

View Archived Issues

New antidiabetic agents discovered at Toray

Antibacterial PDF inhibitors prepared and tested at Senju

Novel 5-HT4 ligands and their use in gastrointestinal disorders

BMS and Pharmacopeia jointly report new p38 kinase inhibitors

Abbott claims selective dopamine D3 modulators for use in psychoses and other disorders

Wyeth researchers identify new EAAT2 inhibitors with potential in schizophrenia

New COX-2 inhibitors covered by Pfizer patents

Basiliximab immunoprophylaxis in the prevention of acute rejection after renal transplantation

Liposomal doxorubicin combined with IL-12 synergistic in HIV-associated KS

Clinical safety and pharmacokinetics of UK-427857 in healthy volunteers

Good safety profile of the IL-2 agonist Bay-50-4798 in cynomolgus monkeys

Viral load reduction with tipranavir/ritonavir related to trough tipranavir plasma levels

diaDexus licenses rights to testisin cancer target

Telik and Vanderbilt-Ingram Cancer Center sign agreement for cancer drug discovery

Ribozyme to secure financing to support development of RNAi therapeutics

Bayer seeks expansion of aspirin labeling to include prevention of first heart attack

Renovis awarded grant to support psychiatric drug discovery

Synaptic shareholders approve merger with Lundbeck

Altus and Dr. Falk form alliance to develop TheraCLEC in Europe

BCY LifeSciences updates status of phase II DCF-987 trial in cystic fibrosis

Avanir generates antibody to neutralize anthrax toxin

AlgoRx acquires rights to novel antimigraine therapy

Effexor XR approved for social anxiety disorder

Targeted intracellular drug delivery demonstrated by Cyclosert

Novel vitamin D analogue with dissociation between immunosuppressive and hypercalcemic effects

Benzophenone NNRTIs characterized in vitro at GSK

Ro-033-4649 holds promise for protease inhibitor-resistant HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...